Back to Journals » Biologics: Targets and Therapy » Volume 12

Biologics: Targets and Therapy


Archive: Volume 12, 2018

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation

Wen M, Xia J, Sun Y, Wang X, Fu X, Zhang Y, Zhang Z, Zhou Y, Li X

Biologics: Targets and Therapy 2018, 12:183-190

Published Date: 30 November 2018

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results

Nozaki Y, Nagare Y, Ashida C, Tomita D, Okada A, Inoue A, Kinoshita K, Funauchi M, Matsumura I

Biologics: Targets and Therapy 2018, 12:171-182

Published Date: 27 November 2018

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product

Singh SK, Pokalwar S, Bose S, Gupta S, Almal S, Ranbhor RS

Biologics: Targets and Therapy 2018, 12:159-170

Published Date: 23 November 2018

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies

Degli Esposti L, Perrone V, Sangiorgi D, Buda S, Andretta M, Rossini M, Girolomoni G

Biologics: Targets and Therapy 2018, 12:151-158

Published Date: 12 November 2018

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis

Heslinga SC, Konings TC, van der Horst-Bruinsma IE, Kamp O, van Halm VP, de Bruin-Bon HACM, Peters MJ, Nurmohamed MT

Biologics: Targets and Therapy 2018, 12:143-149

Published Date: 8 November 2018

Two decades with omalizumab: what we still have to learn

Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E

Biologics: Targets and Therapy 2018, 12:135-142

Published Date: 26 October 2018

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I

Biologics: Targets and Therapy 2018, 12:127-134

Published Date: 25 October 2018

Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus

Kaliamurthi S, Selvaraj G, Kaushik AC, Gu KR, Wei DQ

Biologics: Targets and Therapy 2018, 12:107-125

Published Date: 2 October 2018

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I

Biologics: Targets and Therapy 2018, 12:97-106

Published Date: 2 October 2018

Focus on biosimilar etanercept – bioequivalence and interchangeability

Cantini F, Benucci M

Biologics: Targets and Therapy 2018, 12:87-95

Published Date: 30 August 2018

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y

Biologics: Targets and Therapy 2018, 12:75-86

Published Date: 20 August 2018

The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation

Hakimian S, Popov Y, Rupawala AH, Salomon-Escoto K, Hatch S, Pellish R

Biologics: Targets and Therapy 2018, 12:61-67

Published Date: 27 February 2018

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases

Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F

Biologics: Targets and Therapy 2018, 12:37-41

Published Date: 31 January 2018

Analytical characterization of recombinant hCG and comparative studies with reference product

Thennati R, Singh SK, Nage N, Patel Y, Bose SK, Burade V, Ranbhor RS

Biologics: Targets and Therapy 2018, 12:23-35

Published Date: 30 January 2018

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

Chen YH, Carvalho HMS, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS

Biologics: Targets and Therapy 2018, 12:1-9

Published Date: 12 January 2018